BDBM158478 US10189853, sunitinib::US9029401, Sunitinib::US9695181, Sunitinib

SMILES CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3cccc(F)c23)c1C

InChI Key InChIKey=UQQZPUPMXFCRML-UHFFFAOYSA-N

Data  7 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 158478   

TargetBifunctional epoxide hydrolase 2(Human)
University of California

US Patent
LigandPNGBDBM158478(US9029401, Sunitinib | US9695181, Sunitinib | US10...)
Affinity DataIC50: 1.00E+4nMAssay Description:See reference (Jones, P. D.; Wolf, N. M.; Morisseau, C.; Whetstone, P.; Hock, B.; Hammock, B. D. Anal. Biochem. 343:66-75; 2005) for sEH assay.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/23/2015
Entry Details
Go to US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
University of California

US Patent
LigandPNGBDBM158478(US9029401, Sunitinib | US9695181, Sunitinib | US10...)
Affinity DataIC50: 1.00E+4nMpH: 7.5Assay Description:Inhibitor Concentration at 50% enzyme inhibition (IC50) values were calculated by quantifying the end-point ADP production from each kinase reaction ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/23/2015
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Double Rider Medicine

US Patent
LigandPNGBDBM158478(US9029401, Sunitinib | US9695181, Sunitinib | US10...)
Affinity DataIC50: 6.40nMAssay Description:Inhibition of Compound IIa, IIb, IIc and IId on the Activity of Catalyzing Substrate Phosphorylation of KDR (VEGFR2) Protein Tyrosine Kinase at the M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/26/2018
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Double Rider Medicine

US Patent
LigandPNGBDBM158478(US9029401, Sunitinib | US9695181, Sunitinib | US10...)
Affinity DataIC50: 2.30nMAssay Description:Inhibition of Compound IIa, IIb, IIc and IId on the Activity of Catalyzing Substrate Phosphorylation of KDR (VEGFR2) Protein Tyrosine Kinase at the M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/26/2018
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM158478(US9029401, Sunitinib | US9695181, Sunitinib | US10...)
Affinity DataIC50: 172nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Double Rider Medicine

US Patent
LigandPNGBDBM158478(US9029401, Sunitinib | US9695181, Sunitinib | US10...)
Affinity DataIC50: 18.9nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor alpha(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM158478(US9029401, Sunitinib | US9695181, Sunitinib | US10...)
Affinity DataIC50: 83.1nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent